Approval of Abilify Inj makes confrontation against Janssen’s Invega

In the long-acting injectable(LAI) market for schizophrenia, which has been monopolized by Janssen with Invega Sustenna Inj, Korea Otsuka Pharmaceuticals’ Abilify Inj formed the 2-way competition as acquiring approval.

As having high potential from excellent drug compliance compared to existing oral drugs, the long acting injectable has been claimed to be promptly expanded in the health insura...